Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brenetafusp

Fusion protein · Immune activation, directed at PRAME and CD3 (CD3E) · developed by Immunocore

Phase 3 Most advanced trial
IMCR Developer
2 Registered trials

What is Brenetafusp?

Brenetafusp is a soluble T-cell receptor fused to an anti-CD3 single-chain variable fragment. The T-cell receptor moiety binds PRAME on tumor cells while the anti-CD3 moiety binds T lymphocytes, cross-linking them so that cytotoxic T cells kill PRAME-expressing cells. It is studied in advanced solid tumors and advanced melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IMC-F106C
Drug type
Fusion protein
Targets
PRAME, CD3 (CD3E)
Mechanism
Immune activation, directed at PRAME and CD3 (CD3E)
Pathways
CTL-mediated killing of tumor cells
Therapy area
Oncology
Developer
Immunocore Ltd (IMCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
5GK14JY4JE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06112314 Phase 3 Advanced Melanoma Recruiting IMCR
NCT04262466 Phase 1/2 Select Advanced Solid Tumors Active not recruiting IMCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced MelanomaSelect Advanced Solid Tumors

Other drugs acting on PRAME / CD3E

More from Immunocore

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.

Follow IMCR, the company behind Brenetafusp

See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.